Ocrelizumab
- Generic Name
- Ocrelizumab
- Brand Names
- Ocrevus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 637334-45-3
- Unique Ingredient Identifier
- A10SJL62JY
- Background
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ...
- Indication
用于治疗复发型多发性硬化症（MS）。
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Primary Progressive Multiple Sclerosis (PPMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT02688985
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2020-05-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 608
- Registration Number
- NCT02637856
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center; Department of Neurology, Columbus, Ohio, United States
🇺🇸Allegheny Neurological Associates, Pittsburgh, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2011-08-09
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 835
- Registration Number
- NCT01412333
- Locations
- 🇺🇸
Infinity Clinical Research, Hollywood, Florida, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸Advanced Neurosciences Research LLC, Fort Collins, Colorado, United States
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-11-24
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 821
- Registration Number
- NCT01247324
- Locations
- 🇺🇸
Northwestern University; Dept. of Neurology, Chicago, Illinois, United States
🇺🇸The Minneapolis Clinic of Neurology, Golden Valley, Minnesota, United States
🇺🇸Uni of Vermont Medical Center;, Burlington, Vermont, United States
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-09-03
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 735
- Registration Number
- NCT01194570
- Locations
- 🇺🇸
Maxine Mesinger MS Clinic/Baylor College of Medicine; Neurology, Houston, Texas, United States
🇺🇸Swedish Neuroscience Institute; Multiple Sclerosis Center, Seattle, Washington, United States
🇺🇸MidAmerica Neuroscience Institute, Prairie Village, Kansas, United States
A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab
- Conditions
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00808210
- Locations
- 🇺🇸
Ohio State Univ Med Center, Columbus, Ohio, United States
🇺🇸Ctr for Inflammatory Disease, Nashville, Tennessee, United States
🇺🇸Phillip A Waller MD, PA, Houston, Texas, United States
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00676715
- Locations
- 🇺🇸
Phoenix Neurological Associates Ltd, Phoenix, Arizona, United States
🇧🇬CCB Medical institute, Ministry of Interior Sofia; CLINIC OF NEUROLOGY, Sofia, Bulgaria
🇺🇸MS Center of Vero Beach, Vero Beach, Florida, United States
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT00673920
A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 381
- Registration Number
- NCT00626197
A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)
- First Posted Date
- 2007-10-05
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00539838
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.